one-stage prothrombin test is invaluable as a routine method, and it has been carried out on the plasma of patients with many types of clotting defect. When the one-stage clotting time is lengthened the patient is often said to have "hypoprothrombinaemia." This is misleading, because the test cannot be relied upon to measure prothrombin. Patients with a marked reduction in prothrombin may show little change of clotting time by Quick's method, and patients with no significant reduction in prothrombin may have a grossly lengthened one-stage clotting time. Quick's test is influenced by accelerators of blood coagulation, by the concentration of fibrinogen, and by the presence of inhibitors, such as heparin, in the blood. At present the one-stage test cannot be used as a measure of any specific substance.
The important accelerators which influence the one-stage test are factors V (Owren, 1947) .and VII (Koller, Loeliger, and Duckert, 1951) . Factor V is a protein in the globulin fraction of plasma which is not adsorbed by inorganic precipitates such as Ca3(PO4)2, BaSO4, and AI(OH)3. This substance has been given various names, accelerator globulin (Ware and Seegers, 1948) , prothrombin accelerator (Fantl and Nance, 1948) , and the labile factor (Quick, 1943) . Factor V may be deficient from birth or childhood (Owren, 1947; Frank, Bilhan, and Ekren, 1950; Brink and Kingsley, 1952) , or may become deficient as a result of acute infection (Koller, Gasser, Krusi, and de Muralt, 1950) , or liver disease (Owren, 1949) . Factor VII (Koller et al., 1951 ) is a protein in the globulin fraction of serum which is adsorbed by BaSO4 and Al(OH)3. The activity of factor VII may be identical with the phenomena attributed to prothrombin conversion factor (Owen and Bollman, 1948) , serum prothrombin conversion accelerator (de Vries, Alexander, and Goldstein 1949) , proconvertin and convertin (Owren, 1951a (Owren, , 1951b , and co-thromboplastin (Mann and Hurn, 1951 A rough, quantitative distinction between the effects of factors V, VII, and prothrombin can be achieved by the use of plasma adsorbed with Al(OH)3, which contains factor V but not prothrombin or factor VII, and normal serum, which contains little factor V and prothrombin but much factor VII. The one-stage clotting time of a plasma deficient in factor V will be shortened by the addition of Al(OH)3-treated plasma. The one-stage clotting time of a plasma deficient in factor VII will be shortened by the addition of serum but not by the addition of Al(OH)3-treated plasma. The one-stage clotting time of a plasma deficient in prothrombin will not be shortened by the addition of AI(OH)3-treated plasma or serum.
Although a number of patients with so-called idiopathic hypoprothrombinaemia have been described, in none can the defect be attributed with certainty to a lack of prothrombin alone. In five instances the defect was probably a reduction of factor V (Owren, 1947; Frank et al., 1950;  de Vries, Matoth, and Shamir, 1951; Stohlman, Harrington, and Moloney, 1951; Brink and Kingsley, 1952) . In four instances factor VII may have been deficient (Giordano, 1943; Crockett, Shotton, Craddock, and Leavell, 1949; Landwehr, Lang, and Alexander, 1950; Alexander, Goldstein, Landwehr, and Cook, 1951) . In nine instances the defect was not clearly defined (Rhoads and FitzHugh, 1941; Plum, 1943; Murphy and Clark, 1944; de Marval and Bomchil, 1944; Hauser, 1945; Quick. 1947; Hagen and Watson, 1948; Covey, Cohen, and Papps, 1950; Ferguson, 1950) . The patient to be described had uncomplicated prothrombin deficiency which is, apparently, a very rare condition. The plasma of this patient was useful for the study of coagulation factors. prothrombin was devised. This method will be described in this paper. The patient's plasma was also useful for the study of plasma thromboplastin, and this work is described elsewhere (Biggs, 1952; Biggs, Douglas, and Macfarlane, 1953) .
Methods
Collection of Plasma-Venous blood is collected and mixed with 3.8% sodium citrate in the proportion of 1 part of citrate to 9 parts of blood. The plasma is separated after centrifuging for five minutes at 2,000 r.p.m.
The one-stage method is carried out essentially as described by Quick (1942) . A full account of the method, including the preparation of brain emulsion and M-40 calcium chloride, is given by Biggs (1951) .
Two-stage Method.-Fibrinogen is prepared by the phosphate-buffer method of Jaques (1943) described by Biggs (1951) .
Test.-For the test 0.4 ml. of undiluted citrated plasma is mixed with 0.4 ml. of brain emulsion warmed to 37' C. in a water-bath and 0.4 ml. of M-40 CaCl2 added. As the CaCl2 is added a stop-watch is started, and at 15, 30, and 45 seconds, 1 minute, and thereafter at minute intervals 0.1 -ml. samples are removed from this incubation mixture which is forming thrombin and added to 0.4-ml. amounts of fibrinogen warmed to 37' C. in small tubes. The clotting times of the fibrinogen samples are recorded and the test continued until these exceed three minutes. When the two-stage method is carried out on undiluted plasma thrombin formation and its neutralization by antithrombin are both very rapid. Usually in normal plasma no significant amount of thrombin can be detected after four minutes' incubation. A technical difficulty results from clotting in the incubation mixture. When this occurs the clot must be removed. It has been found that the removal of the clot can be achieved quite easily by winding it on to a wooden swab stick, the end of which has been split and the halves slightly separated. Inexperienced workers may find that this test is best carried out by two operators. One worker removes the 0.1-ml. samples from the incubation mixture and the other records the clotting times of the fibrinogen samples.
Thrombin-Fibrinogen Dilution Curve.-The preparation of this curve is described by Biggs (1951 (Table I) . From these figures the curve of thrombin generation and its disappearance can then be drawn (Fig. 1 ). A ntithrombin.-It is an essential prerequisite of this test that the antithrombin content of the normal and test plasmas should be similar. The antithrombin content of plasma can be tested by the method of Astrup and Darling (1942) . To ensure that the antithrombin is sufficiently normal for the two-stage test a simpler technique may be employed. Sufficient thrombin to clot 1 ml. of plasma in three to four seconds is added to 1 ml. of plasma. At halfminute intervals thereafter 0.1 ml. of the thrombinplasma mixture is added to 0.4 ml. of fibrinogen and the clotting times are recorded. The lengthening of the clotting time with the passage of time should be similar in the normal and patient's plasma. " Thrombin topical" prepared by Roche may be used for this test.
Test for Factor V Deficiency.-The preparation of AI(OH)3a is by the method of Bertho and Grassmann (1938) . Al(OH)3-adsorbed plasma was prepared and described by Biggs (1951) .
Test.-To 0.9 ml. of the plasma to be tested is added 0.1 ml. of Al(OH)s-treated normal plasma. The mixture is tested by the one-stage prothrombin test. Al(OH)3-treated plasma is rich in factor V but poor in prothrombin and factor VII. If the clotting time of the mixture is appreciably shorter than that of the patient's plasma factor V is deficient.
Test for Factor VII Deficiency.-Normal serum is prepared by collecting 3 ml. of normal blood into a glass tube containing three glass beads. The tube is shaken during clotting to ensure that most of the prothrombin is converted to thrombin. After one hour or more at 37°C. the serum can be separated by centrifuging.
Test.-To 0.9 ml. of the plasma to be tested is added 0.1 ml. of serum. The mixture is tested by the one-stage method. Serum is rich in factor VII, but contains little factor V or prothrombin. A marked reduction in clotting time indicates factor VII deficiency.
Case Report G. W. was a man aged 26. The patient had been well until 15 months before investigation. He then developed haematuria, investigation of the renal tract revealing no cause. Nine months later he developed large spontaneous bruises on the right calf, on both arms, and in the neck. There was a history of epistaxis and bleeding from the gums, and also of transient pains in the knees. As a child the patient underwent tonsillectomy, and two years before the onset of his present illness a tooth was removed with no excessive bleeding. There was no history of abnormal bleeding in his relatives. At the time of onset of the bleeding the patient was working in a brewery. Soon afterwards he went to a rubber factory, where he was employed in cutting out from sheets of rubber.
The abnormality in this patient was acquired in adult life and could not easily be attributed to his occupation; nor did he admit to taking any form of medicine.
Clinical examination was negative.
Laboratory Investigations. -Haemoglobin was 13.7 g.%, the white-cell count 5,100 per c.mm. The blood film appeared normal.
Plasma proteins were 6.6 g./100 ml. (albumin, 3.8 g.; globulin, 2.4 g.; fibrinogen, 360 mg.). The thymol turbidity test was negative, as also was the colloidal gold test. The sucrose tolerance curve was normal.
The bilirubin level was 0.3 mg.%.
Fat excretion was normal, with an intake of fat of 280 g. per day and an excretion of fat of 7.2 g. (2.6%).
The bleeding time (Ivy's method) was 5 minutes (normal 2{-7 minutes). A tourniquest test was negative. A platelet count gave 645,000-1,121,000/c.mm.
Investigation of Coagulation Defect.-The wholeblood clotting time, determined by the modified method of Lee and White (1913) From these curves it was calculated that the patient's plasma contained about 11% of the normal amount of prothrombin. The Effect of Vitamin K.-Vitamin K was given to the patient in three different ways with an interval of three days between each trial: 100 mg. of a watersoluble analogue, " synkavit," was given intravenously; 1,000 mg. of vitamin K, was given orally; and 500 mg. of vitamin Ki was given intravenously by the method of Davidson and MacDonald (1943) . In none of these trials did the vitamin K cause a rise in prothrombin tested by the two-stage method.
Effect of Intravenous Administration of Normal Plasma.-Fresh citrated plasma, 860 ml., was given to the patient. The plasma was given within two hours of its collection from three donors. On a second occasion 500 ml. of stored citrated plasma was given to the patient. On each occasion the rise in prothrombin as tested by the two-stage method was slight and the effect transient (Fig. 3) . The ineffectiveness of transfusion suggests either that the normal rate of prothrombin utilization was very high or that it was unusually fast in this patient. This patient is apparently the first to be described in whom a coagulation defect can be attributed to an uncomplicated deficiency of prothrombin. The unusual features of the case are the relatively slight alteration in the one-stage " prothrombin " time and the lengthened whole-blood clotting time. The slight lengthening of the one-stage clotting time suggests that the one-stage test may be relatively more sensitive to changes in the accelerators of blood coagulation than it is to prothrombin. The lengthened wholeblood clotting time may be related to a very low level of thrombin generated by the plasma thromboplastin system when prothrombin is grossly deficient.
The Measurement of Prothrombin The two-stage prothrombin test is usually considered to give the most reliable measure of prothrombin, but it is to be doubted whether this test, as usually interpreted, often gives a true measure of prothrombin in plasma. In experiments in which prothrombin is separated from antithrombin the test can be used to give a measure of prothrombin (Biggs, 1951 ; Biggs and Macfarlane, 1953) . In these artificial conditions prothrombin is quantitatively converted to thrombin, and the amount of thrombin formed gives a measure of prothrombin. In plasma thrombin is neutralized by antithrombin as it is formed, and the amount of thrombin detected in a plasma mixture forming thrombin is not the total amount of thrombin formed, but the amount from which the amount neutralized has been substracted.
The two-stage test is therefore usually carried out on high dilutions of plasma samples to avoid the effects of antithrombin. But it can be shown (Biggs, 1951 ; Biggs and Macfarlane, 1953 ) that dilution does not remove the effects of antithrombin. Moreover, plasma samples in which prothrombin is reduced cannot be greatly diluted because the amount of thrombin to be detected is too low in these diluted samples." If the effedts of antithrombin cannot be eliminated by dilution, it is obviously necessary either to remove antithrombin by some method other than dilution or to devise a test in which the effect of antithrombin is allowed for.
In Fig. 4 Fig. 5d are obtained. In these conditions neither the peak levels of B nor the areas enclosed by the curves are proportional to the amount of A initially present.
If this theoretical model can be followed it is clear that the measurement of the area enclosed by the two-stage curve will give the most generally reliable proportional measure of prothrombin, but that prothrombin cannot be measured unless the level of antithrombin is normal.
It is obviously important to know how closely the blood coagulation reactions approach the theoretical model. When the average of 15 curves for normal plasma is compared with a theoretical model it is found that there is a surprisingly close agreement (Fig. 6) . The amount of prothrombin may be varied by adding prothrombin to the plasma of the prothrombin-deficient patient. When this was done it was found that the experimental curves agreed reasonably well with those of the theoretical model (Fig. 7) .
In the plasma of patients treated with " tromexan" thrombin formation is delayed, and the delay can be reduced by the addition of normal serum. The effect of accelerators on the twostage test can therefore be studied by comparing thrombin formation in "tromexan " plasma with that in " tromexan " plasma to which serum has been added and with that in normal plasma. From  Fig. 8 The speed of neutralization of thrombin can be varied by adding various amounts of heparin to normal plasma. When the two-stage test is carried out on samples containing various amounts of heparin the curves resemble those of the theoretical model (Fig. 9) These curves should be compared with those in Fig. 5 (c (Fig. 10) .
The prothrombin content of a plasma sample can also be measured in the globulin fraction con- taining prothrombin separated from antithrombin (Douglas, 1953 (Douglas, 1953 
